Oxygen Biotherapeutics, Inc. Stock Nasdaq
Equities
US69207P2092
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 6.07M 8.33M |
---|---|---|---|---|---|
Net income 2024 * | -19M -26.06M | Net income 2025 * | -18M -24.69M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.38
x | P/E ratio 2025 * |
-0.83
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.65% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 21-07-13 | |
Director of Finance/CFO | 69 | 01-10 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 21-01-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 14-04-03 |
June Almenoff
BRD | Director/Board Member | 67 | 21-02-24 |
Declan Doogan
BRD | Director/Board Member | 72 | 21-02-24 |
1st Jan change | Capi. | |
---|---|---|
+34.01% | 52.85B | |
-8.02% | 38.87B | |
+34.86% | 38.24B | |
-11.12% | 26.79B | |
+12.56% | 26.16B | |
-19.62% | 19.9B | |
+39.18% | 13.18B | |
+31.47% | 12.24B | |
-3.40% | 11.79B |